These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 32037904)

  • 21. Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance.
    Ghosh AK; Chapsal BD; Weber IT; Mitsuya H
    Acc Chem Res; 2008 Jan; 41(1):78-86. PubMed ID: 17722874
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro activities of nine antifungal drugs and their combinations against Phialophora verrucosa.
    Li Y; Wan Z; Li R
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5609-12. PubMed ID: 24982078
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.
    Arvieux C; Tribut O
    Drugs; 2005; 65(5):633-59. PubMed ID: 15748098
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of Methamphetamine on Spectral Binding, Ligand Docking and Metabolism of Anti-HIV Drugs with CYP3A4.
    Nookala AR; Li J; Ande A; Wang L; Vaidya NK; Li W; Kumar S; Kumar A
    PLoS One; 2016; 11(1):e0146529. PubMed ID: 26741368
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Chemical characteristics, mechanism of action and antiviral activity of darunavir].
    Pasquau Liaño J; Hidalgo Tenorio C
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 10():3-9. PubMed ID: 19195453
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and biological evaluation of novel amprenavir-based P1-substituted bi-aryl derivatives as ultra-potent HIV-1 protease inhibitors.
    Yan J; Huang N; Li S; Yang LM; Xing W; Zheng YT; Hu Y
    Bioorg Med Chem Lett; 2012 Mar; 22(5):1976-9. PubMed ID: 22306123
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy Volunteers.
    Feng HP; Caro L; Fandozzi C; Chu X; Guo Z; Talaty J; Panebianco D; Dunnington K; Du L; Hanley WD; Fraser IP; Mitselos A; Denef JF; De Lepeleire I; de Hoon JN; Vandermeulen C; Marshall WL; Jumes P; Huang X; Martinho M; Valesky R; Butterton JR; Iwamoto M; Yeh WW
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30745392
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Probing multidrug-resistance and protein-ligand interactions with oxatricyclic designed ligands in HIV-1 protease inhibitors.
    Ghosh AK; Xu CX; Rao KV; Baldridge A; Agniswamy J; Wang YF; Weber IT; Aoki M; Miguel SG; Amano M; Mitsuya H
    ChemMedChem; 2010 Nov; 5(11):1850-4. PubMed ID: 20827746
    [No Abstract]   [Full Text] [Related]  

  • 29. Lopinavir and ritonavir act synergistically with azoles against Candida auris in vitro and in a mouse model of disseminated candidiasis.
    Salama EA; Eldesouky HE; Elgammal Y; Abutaleb NS; Seleem MN
    Int J Antimicrob Agents; 2023 Sep; 62(3):106906. PubMed ID: 37392947
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The crystal structure of protease Sapp1p from Candida parapsilosis in complex with the HIV protease inhibitor ritonavir.
    Dostál J; Brynda J; Hrušková-Heidingsfeldová O; Pachl P; Pichová I; Rezáčová P
    J Enzyme Inhib Med Chem; 2012 Feb; 27(1):160-5. PubMed ID: 22146051
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sex hormone effects on Phialophora verrucosa in vitro and characterization of progesterone receptors.
    Hernández-Hernández F; De Bievre C; Camacho-Arroyo I; Cerbon MA; Dupont B; Lopez-Martinez R
    J Med Vet Mycol; 1995; 33(4):235-9. PubMed ID: 8531021
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Co-treatment With HIV Protease Inhibitor Nelfinavir Greatly Increases Late-phase Apoptosis of Drug-resistant KBV20C Cancer Cells Independently of P-Glycoprotein Inhibition.
    Kim JY; Park YJ; Lee BM; Yoon S
    Anticancer Res; 2019 Jul; 39(7):3757-3765. PubMed ID: 31262902
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug-drug interaction between itraconazole and the antiretroviral drug lopinavir/ritonavir in an HIV-1-infected patient with disseminated histoplasmosis.
    Crommentuyn KM; Mulder JW; Sparidans RW; Huitema AD; Schellens JH; Beijnen JH
    Clin Infect Dis; 2004 Apr; 38(8):e73-5. PubMed ID: 15095234
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of lopinavir/ritonavir and lopinavir/ritonavir loaded PLGA nanoparticles on experimental toxoplasmosis.
    Abou-El-Naga IF; El Kerdany ED; Mady RF; Shalaby TI; Zaytoun EM
    Parasitol Int; 2017 Dec; 66(6):735-747. PubMed ID: 28838776
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIV Aspartic Peptidase Inhibitors Modulate Surface Molecules and Enzyme Activities Involved with Physiopathological Events in
    Palmeira VF; Alviano DS; Braga-Silva LA; Goulart FRV; Granato MQ; Rozental S; Alviano CS; Santos ALS; Kneipp LF
    Front Microbiol; 2017; 8():918. PubMed ID: 28579986
    [No Abstract]   [Full Text] [Related]  

  • 36. Non-cleavage site gag mutations in amprenavir-resistant human immunodeficiency virus type 1 (HIV-1) predispose HIV-1 to rapid acquisition of amprenavir resistance but delay development of resistance to other protease inhibitors.
    Aoki M; Venzon DJ; Koh Y; Aoki-Ogata H; Miyakawa T; Yoshimura K; Maeda K; Mitsuya H
    J Virol; 2009 Apr; 83(7):3059-68. PubMed ID: 19176623
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oropharyngeal candidiasis in HIV-infected patients under treatment with protease inhibitors.
    Migliorati CA; Birman EG; Cury AE
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2004 Sep; 98(3):301-10. PubMed ID: 15356467
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Re-emerging Aspartic Protease Targets: Examining
    Kryštůfek R; Šácha P; Starková J; Brynda J; Hradilek M; Tloušt'ová E; Grzymska J; Rut W; Boucher MJ; Drąg M; Majer P; Hájek M; Řezáčová P; Madhani HD; Craik CS; Konvalinka J
    J Med Chem; 2021 May; 64(10):6706-6719. PubMed ID: 34006103
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aspartic protease inhibitors as potential anti-Candida albicans drugs: impacts on fungal biology, virulence and pathogenesis.
    Braga-Silva LA; Santos AL
    Curr Med Chem; 2011; 18(16):2401-19. PubMed ID: 21568917
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Secretory aspartyl peptidase activity from mycelia of the human fungal pathogen Fonsecaea pedrosoi: effect of HIV aspartyl proteolytic inhibitors.
    Palmeira VF; Kneipp LF; Alviano CS; dos Santos AL
    Res Microbiol; 2006 Nov; 157(9):819-26. PubMed ID: 16959473
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.